Cardiac myosin inhibitors in hypertrophic cardiomyopathy. [PDF]
J Cardiovasc ImagingAbstract Mavacamten, the first selective and reversible cardiac myosin inhibitor (CMI), has been introduced to the clinical arena for the treatment of obstructive hypertrophic cardiomyopathy (HCM). By reducing excessive actin-myosin cross-bridging, this agent decreases myocardial contractility and alleviates the dynamic left ventricular ...
Lim J, Kim HK.
europepmc +2 more sources
Cardiac Myosin Inhibitors in Hypertrophic Cardiomyopathy: From Sarcomere to Clinic. [PDF]
Int J Mol SciHypertrophic cardiomyopathy (HCM) is a primary myocardial disease characterized by unexplained left ventricular hypertrophy, often resulting from pathogenic variants of sarcomeric protein genes. Conventional treatments, such as the use of beta blockers or calcium channel blockers, focus on symptomatic control but do not address the underlying ...
Nakamura K +7 more
europepmc +3 more sources
Cardiac myosin inhibitors: Efficacy, safety and future directions of aficamten in hypertrophic obstructive cardiomyopathy. [PDF]
Egypt Heart JAbstract Background Hypertrophic obstructive cardiomyopathy (HOCM) is a genetic disorder that affects the cardiac myocytes leading to asymmetric hypertrophy of the left ventricle and obstruction of the left ventricular outflow tract (LVOT) with possible risk of sudden cardiac death in some high-risk patients.
Ogieuhi IJ +14 more
europepmc +4 more sources
Cardiac Myosin Inhibitors in the Treatment of Hypertrophic Cardiomyopathy: Clinical Trials and Future Challenges. [PDF]
BiomoleculesHypertrophic cardiomyopathy (HCM) is a prevalent and often underdiagnosed genetic cardiac disorder characterized by left ventricular hypertrophy and, in many cases, dynamic left ventricular outflow tract obstruction (LVOTO). The development of cardiac myosin inhibitors (CMIs) represents an emerging therapeutic approach in the pharmacological management
Kukowka A, Droździk M.
europepmc +2 more sources
Cardiac myosin inhibitors: a silver lining for an old disease. [PDF]
Open HeartYadav S, Agstam S, Singh S.
europepmc +3 more sources
Activin-A and Bmp4 Levels Modulate Cell Type Specification during CHIR-Induced Cardiomyogenesis [PDF]
, 2015 The use of human pluripotent cell progeny for cardiac disease modeling, drug testing and therapeutics requires the ability to efficiently induce pluripotent cells into the cardiomyogenic lineage.
Blinka, Steven +8 more
core +21 more sources
Cardiac Myosin Inhibitors in Hypertrophic Cardiomyopathy: Clinical Advances and Therapeutic Prospects. [PDF]
Drug Des Devel TherHou L, Lin B, Ji X, Huang A.
europepmc +3 more sources
Speckle-tracking echocardiography combined with imaging mass spectrometry assesses region-dependent alterations [PDF]
, 2020 Left ventricular (LV) contraction is characterized by shortening and thickening of longitudinal and circumferential fibres. To date, it is poorly understood how LV deformation is altered in the pathogenesis of streptozotocin (STZ)-induced type 1 diabetes
Dong, Fengquan +10 more
core +1 more source
Micro-RNAS that control myosin expression and myofiber identity [PDF]
, 2015 The present invention relates to the identification of two microRNAs, miR-499 and miR-208b, that repress fast skeletal muscle contractile protein genes. Expression of miR-499 and/or miR-208b can be used to repress fast fiber genes and activate slow fiber
Olson, Eric N., van Rooij, Eva
core +1 more source
Metabolic and cardiac adaptation to chronic pharmacologic blockade of facilitative glucose transport in murine dilated cardiomyopathy and myocardial ischemia [PDF]
, 2018 GLUT transgenic and knockout mice have provided valuable insight into the role of facilitative glucose transporters (GLUTs) in cardiovascular and metabolic disease, but compensatory physiological changes can hinder interpretation of these models.
Heitmeier, Monique R. +6 more
core +2 more sources